{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.777","value":"-4.12"},{"groupId":"OG001","spread":"26.406","value":"-4.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"332"},{"groupId":"OG001","value":"316"}],"units":"Participants"}],"title":"Cycle 2, Day 1 (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.824","value":"-8.60"},{"groupId":"OG001","spread":"29.059","value":"-8.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"title":"C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.598","value":"-11.19"},{"groupId":"OG001","spread":"30.181","value":"-11.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"title":"C4D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.065","value":"-12.41"},{"groupId":"OG001","spread":"31.752","value":"-9.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"213"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.251","value":"-13.33"},{"groupId":"OG001","spread":"28.142","value":"-11.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"title":"C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.601","value":"-13.12"},{"groupId":"OG001","spread":"31.691","value":"-12.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.179","value":"-13.22"},{"groupId":"OG001","spread":"30.429","value":"-5.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"C12D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.116","value":"-15.65"},{"groupId":"OG001","spread":"31.254","value":"-19.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"C15D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.777","value":"-16.16"},{"groupId":"OG001","spread":"27.340","value":"-15.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"C18D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.546","value":"-17.70"},{"groupId":"OG001","spread":"26.227","value":"-19.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"C21D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.773","value":"-18.30"},{"groupId":"OG001","spread":"23.002","value":"-28.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"C24D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.041","value":"-17.75"},{"groupId":"OG001","spread":"27.889","value":"-26.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"C27D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.882","value":"-18.94"},{"groupId":"OG001","spread":"33.333","value":"-16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"C30D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.222","value":"-18.38"},{"groupId":"OG001","spread":"41.944","value":"-8.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"C33D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.527","value":"-22.22"},{"groupId":"OG001","spread":"23.570","value":"-16.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"C36D1"},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"C39D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"EORTC QLQ-LC13 is a 13-item questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia). Reported here are the EORTC lung cancer coughing scores only. Scores were calculated and transformed to a range from 0 to 100, with a higher score representing a higher level of symptoms/problems and a negative change from baseline value indicating reduction (i.e. improvement) in symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"FAS included all randomized participants. Overall number of participants analysed = participants evaluable for the outcome measure. Number analyzed = participants evaluable at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39","title":"Change From Baseline in Coughing Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)","type":"SECONDARY","unitOfMeasure":"score on a scale"}